Volume 13 - Number 1

January - March 2011



Dyslipidemia Related to Antiretroviral Therapy


Vicente Estrada and Joaquín Portilla   |Full Article in PDF|

Department of Infectious Diseases, Hospital Clínico San Carlos, Madrid, Spain


Abstract

Dyslipidemia is frequently observed in HIV-infected patients. Its pathogenesis is complex and includes factors related to the virus, the host, and antiretroviral treatment. Dyslipidemia is a main cardiovascular risk factor and it is partially modifiable. Whereas HIV infection and its treatment are associated with a state of accelerated atherosclerosis and an increase in the number of cases of myocardial infarction, dyslipidemia management must be a priority in the clinical care of patients with HIV infection. In this review, we discuss the major pathogenic mechanisms of dyslipidemia associated with antiretroviral therapy and the effect of the currently used drugs on the lipid profile. The current recommendations for dyslipidemia management include the control of other cardiovascular risk factors, the choice of antiretroviral drugs with a better lipid profile, and lipid-lowering drug use when clinically indicated.


Key Words:

Dyslipidemia. HIV infection. Antiretroviral therapy. Cardiovascular risk.






Contact Us

Permanyer Publications

  • Mallorca, 310 Barcelona, Spain.  08037
Phone / Fax
  • +34 93 207 59 20
  • +34 93 457 66 42
Email
  • permanyer@permanyer.com




     © 2017 Permanyer Publications  -  Legal Notice - Cookies Policy  -  ISSN 1698-6996